Tokyo Tape
Sign in
← Chiome Bioscience

Half-year report · Q2

4583.TEDINET S100U79O
Period2024-01-01 → 2024-06-30
Filed2024-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥359m2023-01-01 → 2023-06-30StandaloneNet sales
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Operating income−¥659m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥662m2023-01-01 → 2023-06-30StandaloneOrdinary income
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax−¥661m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥664m2023-01-01 → 2023-06-30StandaloneProfit loss
Total assets¥1.6bnat 2024-06-30StandaloneAssets
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥1.7bnat 2023-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥487mat 2024-06-30StandaloneLiabilities
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2023-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥595m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥82,0002023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥113m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-13.72023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio67.2%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,503,800at 2023-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥266m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-06-30−¥602m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-06-30¥209m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30−¥393m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 447
ItemContextValueUnit
Accounts receivable tradeCurrentQuarterInstant_NonConsolidatedMember50693000JPY
InventoriesPrior1YearInstant_NonConsolidatedMember64107000JPY
InventoriesCurrentQuarterInstant_NonConsolidatedMember52443000JPY
Advance payments tradePrior1YearInstant_NonConsolidatedMember86797000JPY
Advance payments tradeCurrentQuarterInstant_NonConsolidatedMember106909000JPY
Consumption taxes receivablePrior1YearInstant_NonConsolidatedMember25046000JPY
Consumption taxes receivableCurrentQuarterInstant_NonConsolidatedMember15323000JPY
Other caPrior1YearInstant_NonConsolidatedMember44695000JPY
Other caCurrentQuarterInstant_NonConsolidatedMember92379000JPY
Current assetsPrior1YearInstant_NonConsolidatedMember1629396000JPY
Current assetsCurrentQuarterInstant_NonConsolidatedMember1421405000JPY
Machinery and equipmentPrior1YearInstant_NonConsolidatedMember233509000JPY
Machinery and equipmentCurrentQuarterInstant_NonConsolidatedMember233509000JPY
Accumulated depreciation machinery and equipmentPrior1YearInstant_NonConsolidatedMember-232343000JPY
Accumulated depreciation machinery and equipmentCurrentQuarterInstant_NonConsolidatedMember-232930000JPY
Machinery and equipment netPrior1YearInstant_NonConsolidatedMember1166000JPY
Machinery and equipment netCurrentQuarterInstant_NonConsolidatedMember579000JPY
Tools furniture and fixturesPrior1YearInstant_NonConsolidatedMember85451000JPY
Tools furniture and fixturesCurrentQuarterInstant_NonConsolidatedMember82364000JPY
Accumulated depreciation tools furniture and fixturesPrior1YearInstant_NonConsolidatedMember-85451000JPY
Accumulated depreciation tools furniture and fixturesCurrentQuarterInstant_NonConsolidatedMember-82364000JPY
Tools furniture and fixtures netPrior1YearInstant_NonConsolidatedMember0JPY
Tools furniture and fixtures netCurrentQuarterInstant_NonConsolidatedMember0JPY
Property plant and equipmentPrior1YearInstant_NonConsolidatedMember1166000JPY
Property plant and equipmentCurrentQuarterInstant_NonConsolidatedMember579000JPY
Long term prepaid expensesPrior1YearInstant_NonConsolidatedMember8081000JPY
Long term prepaid expensesCurrentQuarterInstant_NonConsolidatedMember22643000JPY
Lease and guarantee depositsPrior1YearInstant_NonConsolidatedMember112811000JPY
Lease and guarantee depositsCurrentQuarterInstant_NonConsolidatedMember112811000JPY
Other ioaPrior1YearInstant_NonConsolidatedMember0JPY
Other ioaCurrentQuarterInstant_NonConsolidatedMember0JPY
Investments and other assetsPrior1YearInstant_NonConsolidatedMember120892000JPY
Investments and other assetsCurrentQuarterInstant_NonConsolidatedMember135454000JPY
Noncurrent assetsPrior1YearInstant_NonConsolidatedMember122058000JPY
Noncurrent assetsCurrentQuarterInstant_NonConsolidatedMember136034000JPY
AssetsPrior1YearInstant_NonConsolidatedMember1751454000JPY
AssetsCurrentQuarterInstant_NonConsolidatedMember1557439000JPY
Accounts payable tradePrior1YearInstant_NonConsolidatedMember37735000JPY
Accounts payable tradeCurrentQuarterInstant_NonConsolidatedMember23014000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember291000000JPY
Short term loans payableCurrentQuarterInstant_NonConsolidatedMember292100000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember116952000JPY
Accounts payable otherCurrentQuarterInstant_NonConsolidatedMember63872000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember25587000JPY
Accrued expensesCurrentQuarterInstant_NonConsolidatedMember24369000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember23952000JPY
Income taxes payableCurrentQuarterInstant_NonConsolidatedMember11357000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember31200000JPY
Advances receivedCurrentQuarterInstant_NonConsolidatedMember9100000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember5880000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass